series-c-plus
Stage
1
Investors
About
Umoja Biopharma develops in vivo CAR T cell therapies for cancer treatment using its proprietary VivoVec platform, which generates CAR T cells directly within patients to simplify and accelerate therapy delivery.
Explore Umoja Biopharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.